Skip to main content
SpringerLink
Log in

Progestogens in Non-gynecological Indications

  • Chapter
Progestogens in Obstetrics and Gynecology

  • 1152 Accesses

Abstract

A whole “orchestra” of hormones and enzymes are required in order to achieve an optimal hormonal supply for bodily functions. Progesterone appears to be the key factor for health not only in women, but also in men and children, in patients with depression, sleep disorders, multiple sclerosis, spinal cord neurodegeneration, brain trauma, CVA, epileptic seizures, prostate hyperplasia, erectile dysfunction and more. Progesterone affects sexual behavior, has anti-inflammatory and anti-oxidative effects, is a mild diuretic, a natural anti-convulsive, supports the thyroid function and helps to normalize blood-sugar, zinc and copper levels.

Since progesterone activates the tumor-suppressor gene p53, suppresses the tumor-supporting gene Bcl2, promotes apoptosis and prevents metastasis by inhibiting matrix metalloproteinases, its supplementation in cases of progesterone deficiency is of importance for cancer prophylaxis.

Furthermore, progesterone is responsible for a number of physiological processes: Interaction with the GABA receptor complex in the brain, leading to sedative and anxiolytic effects and better quality of sleep, as well as interactions with fatty tissue and the kidneys. Progesterone increases pulmonary gas exchange, reduces alveolar CO2 pressure and displays immune-suppressive effects.

An erratum to this chapter is available at http://dx.doi.org/10.1007/978-3-319-14385-9_15

An erratum to this chapter can be found at http://dx.doi.org/10.1007/978-3-319-14385-9_15

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee JR. Hormone balance for men. What your doctor may not tell you about prostate health and natural hormone supplementation. One to One Inc. P.O. Box 84900 Phoenix, AZ 85071;2007, (800) 528–0559.

    Google Scholar 

  2. Inue T, Akahira JL, Suzuki T, Darnel AD, Kaneko C, Takaha K, et al. Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab. 2002;87(11):5325–31.

    Article  Google Scholar 

  3. Koenig HL, Schuhmacher M, Ferzaz B, Do Thi AN, Ressouches A, Guennoun R, Jung-Testas I, Robel P, Akwa Y, Baulieu EE. Progesterone synthesis and myelin formation by Schwann cells. Science. 1995;268(5216):1500–3.

    Article  CAS  PubMed  Google Scholar 

  4. Srinivasan G, Cambell E, Beshirelahi N. Androgens, estrogens and progesterone receptors in normal and aging prostates. Microsc Res Tech. 1995;30(4):293–304.

    Article  CAS  PubMed  Google Scholar 

  5. Inue T, Akahira JL, Takeyama J, Suzuki T, Darnel AD, Kaneko C, Kurokawa Y, Satomi S, Sanano H. Spacial and topological distribution of progesterone receptor A and B isoforms during human development. Mol Cell Endocrinol. 2001;182(1):83–9.

    Article  Google Scholar 

  6. Ariga N, Suzuki T, Moriya T, Kimura M, Inoue T. Progesterone receptor A and B isoforms in the human breast and its disorders. J Endocrinol Metab. 2004;89(3):1429–42.

    Article  Google Scholar 

  7. Brady BM, Anderson RA, Kinniburgh D, Baird DT. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. Clin Endocrinol (Oxf). 2003;58(4):506–12.

    Article  CAS  Google Scholar 

  8. Gröschl M, Rauh M, Dörr H-J. Circadian rhythm of salivary cortisol, 17α- hydroxy progesterone and progesterone in healthy children. Clin Chem. 2003;49:1688–91.

    Google Scholar 

  9. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PGV, Katzenellenbogen BS, Martini L, Motta M, Poletti A. The androgen derivative 5α-androstane-3β, 17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype. Cancer Res. 2005;65(12).

    Google Scholar 

  10. Mauvais-Jarvis P, Kuttenn F, Baudet N. Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone. J Clin Endocrinol Metab. 1974;38(1):142–7.

    Article  CAS  PubMed  Google Scholar 

  11. Bonkhoff H, Fixemer T. Bedeutung der Östrogene und ihrer Rezeptoren für die Entstehung und Progression des Prostatakarzinoms. Der Pathologe. 2005;26(6):461. 46.

    Article  CAS  PubMed  Google Scholar 

  12. Andersen ML, Tufic S. Does male sexual behavior require progesterone? Brain Res Rev. 2006;51(1):36–43.

    Article  Google Scholar 

  13. Witt DM, Young LJJ, Crews D. Progesterone modulation of androgen dependent sexual behavior in male rats. Physiol Behav. 1995;57(2):307–13.

    Article  CAS  PubMed  Google Scholar 

  14. De Lignieres B, Beausang A, Faltot M. Acute anxiolytic effect of oral administration of progesterone in men: a double-blind crossover study. Second international symposium of premenstrual, postpartum and menopausal mood disorders. September Kiahaj Island, SC, USA; 1987.

    Google Scholar 

  15. Fries E, Tagaya H, Trachsel L, Holsboer F, Rupprecht R. Progesterone- induced changes in sleep in male subjects. Am J Physiol. 1997;272:E885–91.

    Google Scholar 

  16. Saaressranta T, Polo-Kantola P, Irjala K, Helenius H, Polo O. Respiratory insuffiency in postmenopausal women: Sustained improvement of gas exchange with short-term medroxyprogesterone acetate. Chest. 1999;115(6):1581–87.

    Article  Google Scholar 

  17. Saaressranta T, Polo-Kantola P, Rauhala E, Polo O. Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep. Eur Respir J. 2001;18:989–95.

    Article  Google Scholar 

  18. Platt ME. The miracle of bio-identical hormones. Clancy Lane Publishing, Rancho Mirage, USA. ISBN 978-0-9776683-2-8.

    Google Scholar 

  19. Cuchacovich M, Tchernitchin A, Gatica H, Wurgaft R, Valenzula C, Cornejo E. Intraarticular progesterone: effects of a local treatment for rheumatoid arthritis. J Rheumatol. 1988;15(4):561–65.

    CAS  PubMed  Google Scholar 

  20. Ginanneschi F, Milani P, Filippou G, Mondelli M, Frediani B, Melcangi RC, Rossi A. Evidences for antinociceptive effect of 17-alpha-hydroxy progesterone caproate in carpal tunnel syndrome. J Mol Neurosci. 2012;47(1):59–66.

    Article  CAS  PubMed  Google Scholar 

  21. Rylance PB, Brincat M, Lafferty K, De Trafford JC, Brincat S, Parsons V, Studd JW. Natural progesterone and antihypertensive action. BMJ. 1985;290:13–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Reddy DS. Role of neurosteroids in catamenial epilepsy. Neurotherapeutics. 2009;6(2):392–401.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Tranquilli AL, Mazzini L, Cugini AM, Cester N, Garzetti GG, Romanini C. Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Gynecol Endocrinol. 1995;9(2):137–41.

    Article  CAS  PubMed  Google Scholar 

  24. Burnett CC, Reddi AH. Influence of estrogen and progesterone on matrix-induced endochondral bone formation. Calcif Tissue Int. 1983;35:609–14.

    Article  CAS  PubMed  Google Scholar 

  25. Rimkus V (2000) Der Mann im Wechsel seiner Jahre. Arche Noah, Musik- und Buchverlag D-86971 Peiting. 3. Auflage ISBN 10:3-86733-000-X.

    Google Scholar 

  26. Baulieu EE, Schuhmacher M. Neuro steroids, with special references to the effect of progesterone on myelination in peripheral nerves. Mult Scler. 1997;3:105–12.

    Google Scholar 

  27. Schuhmacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, Gonzales Deniselle MC, Gonzales SL, Ibanez C, Labombarda F, Coirini H, Beaulieu EE, De Nicola AF. Local synthesis and dual actions of progesterone in the nervous system: Neuroprotection and myelination. Growth Horm IGF Res. 2004;14(Suppl A):S18–33.

    Article  Google Scholar 

  28. Chen JL, Lin QH, Fang XL, Tao GS, Huang FY. Effect of progesterone on the secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 in human ectopic endometrial stromal cells. Zhong Nan Da Xue Bao Yi Xue Ban. 2005;30(3):307–11.

    CAS  Google Scholar 

  29. Confavreux C, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339:285–91.

    Article  CAS  PubMed  Google Scholar 

  30. Garay LI, et al. Progesterone down-regulates spinal cord inflammatory mediators and increases myelination in experimental autoimmune encephalomyelitis. Neuroscience. 2012;226:40–50.

    Article  CAS  PubMed  Google Scholar 

  31. Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol. 2002;178(1):59–67.

    Article  CAS  PubMed  Google Scholar 

  32. Wright DW, Kellermann AL, Hertzberg VS, et al. Pro TECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49(4):391–402.

    Article  PubMed  Google Scholar 

  33. Xiao G, Wei J, Yan W, Lu Z. Improved outcomes from administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008;12(2):R61.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Ishrat T, Sayeed I, Atif F, Stein DG. Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res. 2009;1257:94–101.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Cekic M, Cutler SM, Valandingham JW, Stein DG. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol Aging. 2011;32(5):864–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Wang J, Jiang C, Li X, et al. The protective mechanism of progesterone on blood–brain barrier in cerebral ischemia in rats. Brain Res Bull. 2009;9(6):426–30.

    Article  Google Scholar 

  37. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized motor seizures. Neurology. 1995;45:1660–2.

    Article  CAS  PubMed  Google Scholar 

  38. Bauer J, Hocke A, Elger CE. Katameniale Anfälle: Eine Analyse. Nervenarzt. 1995;66:760–9.

    CAS  Google Scholar 

  39. Herzog AG. Three patterns of catamenial seizures. Epilepsia. 1997;38:1082–8.

    Article  CAS  PubMed  Google Scholar 

  40. Bauer J, Burr W, Elger CE. Seizure occurrence during ovulatory and anovulatory cycles in patients with temporal lobe epilepsy: a prospective study. Eur J Neurol. 1998;5:83–8.

    Article  PubMed  Google Scholar 

  41. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999;52(9):1917–8.

    Article  CAS  PubMed  Google Scholar 

  42. Edwards HE, Epps T, Carlen P, Mac Lusky N J. Progesterone receptors mediate progesterone suppression of epilepti form activity in tetanized hippocampal slices in vitro. Neuroscience. 2000;101(4):895–909.

    Article  CAS  PubMed  Google Scholar 

  43. Herzog AG, Friedman MN, Freund S, Pascal-Leone A. Transcranial magnetic stimulation evidence of a potential role for progesterone in the modulation of premenopausal corticocortical inhibition in a woman with catamenial seizure exacerbation. Epilepsy Behav. 2000;2(4):367–9.

    Article  Google Scholar 

  44. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol. 2003;53(3):390–1.

    Article  CAS  PubMed  Google Scholar 

  45. Bauer J (2004) Warum treten epileptische Anfälle kurz vor der Periode auf? Informationspool Epilepsie. Dt. Gesellschaft für Epileptologie.

    Google Scholar 

  46. Reddy DS. Role of neurosteroids in catamenial epilepsy. Epilepsy Res. 2004;62(2–3):99–118.

    Article  CAS  PubMed  Google Scholar 

  47. Harden CL, Herzog AG, Nokolov BG, Koppel BS, Christos PJ, Fowler K, Labar DR, Hauser WA. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsy. 2006;47(9):1447–51.

    Article  CAS  Google Scholar 

  48. Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics. 2009;6(2):392–401.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Diaz NF, Gueerra-Arraiza CH, Diaz NE, Salazar P, Molina-Hernandez A, Camacho-arroyo I, Velasco I. Changes in the content of estrogen α and progesterone receptors during differentiation of mouse embryonic stem cells to dopamine neurons. Brain Res Bull. 2007;73:75–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Gomula A. Successful treatment of parkinsonism with HCG: preliminary findings. Presented at the 4th ISSAM conference in Prague. 2004.

    Google Scholar 

  51. Gonzales Demiselle MC, Lopez Costa JJ, Gonzales SL, Labombarda F, Garay L, Guennounoun R, Schuhmacher M, De Nicola AF. Basis of Protection in spinal cord neurodegeneration. J Steroid Biochem Mol Biol. 2002;83(1–5):199–209.

    Article  Google Scholar 

  52. Trotter A, Maier L, Pohlandt F. Management of the extremely preterm infant: is the replacement of estradiol and progesterone beneficial? Pediatr Drugs. 2001;3(9):629–37.

    Article  CAS  Google Scholar 

  53. Trotter A, Bokelmann B, Sorgo W, Bechinger-Kornhuber D, Heinemann H, Schmücker G, Oesterle M, Köhntop B, Brisch KH, Pollandt F. Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement. J Clin Endocrinol Metab. 2001;86(2):601–3.

    Article  CAS  PubMed  Google Scholar 

  54. Tanner M. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):S13–23.

    Article  Google Scholar 

  55. Stark M. Hypothyroidism Type 2: the epidemic. Revisedth ed. Columbia, MO: Mark Starr Trust; 2013.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Foederatio Medicorum Helveticorum (F.M.H.), CH-3000, Bern, 15, Switzerland

    Christa Nadjafi-Triebsch M.D.

  2. Aerztekammer Nordrhein/Germany (A.E.K.N.O.), Tersteegenstr.9, D-40474, Düsseldorf/Golzheim, Germany

    Christa Nadjafi-Triebsch M.D.

  3. German Society of Anti-Aging Medicine e.V. (G.S.A.A.M.), Vallstedter Weg 114, D-38268, Lengede, Germany

    Christa Nadjafi-Triebsch M.D.

  4. Swiss Society for Anti Aging Medicine and Prevention (S.S.A.A.M.P.), Industriestrasse 3, CH-6345, Neuheim/Zug, Switzerland

    Christa Nadjafi-Triebsch M.D.

Authors
  1. Christa Nadjafi-Triebsch M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tel Aviv University, Tel Aviv, Tel Aviv, Israel

    Howard J.A. Carp

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Nadjafi-Triebsch, C. (2015). Progestogens in Non-gynecological Indications. In: Carp, H. (eds) Progestogens in Obstetrics and Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-319-14385-9_14

Download citation

Publish with us

Policies and ethics

Search

Navigation